National Advisory Committee on Immunization

Last updated
National Advisory Committee on Immunization
Comité consultatif national de l'immunisation
Agency overview
Formed1964 (1964)
Jurisdiction Government of Canada
Headquarters Ottawa, Ontario
Minister responsible
Agency executives
Parent agency Public Health Agency of Canada
Website https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html

The National Advisory Committee on Immunization (NACI; French : Comité consultatif national de l'immunisation; CCNI) is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization. [1]

Contents

History

The NACI's precursor, The National Advisory Committee on Immunizing Agents, was established in 1964. And it was mandated to provide advice on immunizing agents to the Department of National Health and Welfare. In 1975, focus on advice related to the introduction of new vaccines and to assist in the development of immunization programs became the new mandate of the committee. In 1978, the committee was officially renamed into The National Advisory Committee on Immunization, in order to reflect the new mandate for consideration of procedures related to immunization and immunization coverage. [2]

Role

NACI is mandated to provide the Public Health Agency of Canada (PHAC) with medical, scientific, and public health advice relating to vaccines, including the use of vaccines in humans, vaccine evaluation, and the monitoring of vaccine-associated adverse events. [3]

Membership

The NACI is composed of 14 voting members (chair, vice-chair, and 12 voting members), executive secretary, roughly a dozen industry liaison representatives, and roughly a dozen ex-officio professional public service representatives from Health Canada. NACI's voting members composed of experts in the fields of immunization, public health, vaccine preventable diseases, pediatric or adult infectious diseases, allergy/immunology, other health related fields. [3] [4]

As of May 2024, the membership of NACI consists of: [4]

COVID-19 pandemic

NACI became prominent during the COVID-19 pandemic, as publisher of recommendations and guidance surrounding distribution of COVID-19 vaccines. [1] [5] Some of NACI's recommendations have been criticized as counter-productive in terms of public health and communications concerning the pandemic. [6]

Dose scheduling

In March 2021, amid supply shortages, NACI issued a strong recommendation that second doses of two-dose COVID-19 vaccines (such as the AstraZeneca, Moderna, and Pfizer vaccines) be given up to four months after the first, as opposed to the three-to-four week intervals used in the clinical trials and recommended by Health Canada. NACI stated that this recommendation was based on modelling from data showing that "the first two months of real world effectiveness are showing sustained high levels of protection." [6]

Pfizer Canada president Cole Pinnow warned against the recommendation in the House of Commons, stating that "the data that we’ve seen from a real world evidence perspective that has been used to make arguments to extend the dose schedule has been done on much younger populations", and that "we don't have any data after two months to know what the impact of one dose will be." [7]

On May 28, citing improved vaccine availability, NACI recommended that second doses be administered "as soon as possible", and especially to individuals who are at high risk, but that it "continues to recommend that jurisdictions should maximize the number of individuals benefiting from the first dose of a COVID-19 vaccine by extending the second dose of COVID-19 vaccine up to four months after the first." [8] [9]

mRNA vaccine preference

On May 4, 2021, NACI issued a recommendation that mRNA-based vaccines should be preferred over viral vector vaccines such as the AstraZeneca and Janssen vaccines, due to the rare risk of vaccine-induced immune thrombotic thrombocytopenia (VITT). Vice-chairman Shelley Deeks stated that "individuals need to have an informed choice to be vaccinated with the first vaccine that's available, or to wait for an mRNA vaccine." [10]

Various politicians and public health authorities argued that such statements concerning officially-approved vaccines would encourage hesitancy, and impede the public health goal of inoculating the public as quickly as possible. [10] On May 6, NACI issued a follow-up statement wishing to clarify that their previous statement was not to imply that anyone taking a vaccine such as AstraZeneca was making a mistake, and that it was adequately effective for protecting against COVID-19. [11]

Dose mixing

On 1 June 2021, NACI issued a recommendation that those who had received the AstraZeneca vaccine as their first dose may safely receive an mRNA vaccine as their second dose instead. The recommendation cited studies occurring in Europe over similar mixing of doses being performed due to concerns over the AstraZeneca vaccine, including one that showed a sevenfold increase in antibody presence in patients who received AstraZeneca as their first dose and Pfizer as their second. It is still recommended that those who received an mRNA vaccine as a first dose receive the same vaccine for their second dose, but that the two mRNA vaccines can be interchangeable if supply is limited. [12]

Public health officials warned that Canada's use and orders of the AstraZeneca had to be controlled in order to prevent waste, especially as those concerned over VITT (which was associated more with the first dose) request an mRNA option for their second dose instead. [13]

Some countries and non-Canadian businesses have refused to recognize individuals that have received mixed doses as being fully vaccinated; at U.S.-based ports, multiple cruise lines stated that they would only accept passengers fully vaccinated in means approved by the US FDA (only accepting matching does of the Moderna or Pfizer vaccine, or the Janssen vaccine). In mid-July, Prime Minister Justin Trudeau stated that they were "going to work with the international community to make sure that people who are fully vaccinated in ways that Canadians recognize as safe and effective are also recognized around the world." [14] [15] [16]

See also

Related Research Articles

The Therapeutic Goods Administration (TGA) is the medicine and therapeutic regulatory agency of the Australian Government. As part of the Department of Health and Aged Care, the TGA regulates the safety, quality, efficacy and advertising in Australia of therapeutic goods. Therapeutic goods include goods that are represented to have a therapeutic effect, are included in a class of goods the sole or principal use of which is a therapeutic use, or are otherwise determined to be a therapeutic good through a legislative instrument under the Therapeutic Goods Act 1989. Goods that are therapeutic goods must be entered on the Australian Register of Therapeutic Goods (ARTG), or otherwise be the subject of an exemption, approval or authority by the TGA under the Therapeutic Goods Act 1989, Therapeutic Goods Regulations 1990 or Therapeutic Goods Regulations 2002 before they can be imported, supplied, exported or manufactured in Australia.

<span class="mw-page-title-main">Booster dose</span> Additional administration of vaccine

A booster dose is an extra administration of a vaccine after an earlier (primer) dose. After initial immunization, a booster provides a re-exposure to the immunizing antigen. It is intended to increase immunity against that antigen back to protective levels after memory against that antigen has declined through time. For example, tetanus shot boosters are often recommended every 10 years, by which point memory cells specific against tetanus lose their function or undergo apoptosis.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland may choose to accept its advice.

<span class="mw-page-title-main">Oxford–AstraZeneca COVID-19 vaccine</span> Viral vector vaccine for prevention of COVID-19

The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.

The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.

<span class="mw-page-title-main">Deployment of COVID-19 vaccines</span> Distribution and administration of COVID-19 vaccinations

As of 12 August 2024, 13.53 billion COVID-19 vaccine doses have been administered worldwide, with 70.6 percent of the global population having received at least one dose. While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">COVID-19 vaccination in Australia</span> Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.

<span class="mw-page-title-main">COVID-19 vaccination in the Republic of Ireland</span> Immunisation plan against COVID-19

The COVID-19 vaccination programme in the Republic of Ireland is an ongoing mass immunisation campaign that began on 29 December 2020 in response to the COVID-19 pandemic in the Republic of Ireland. Ireland's vaccination rollout has been praised as one of the most successful rollouts in the world and was ranked number one in the European Union in terms of its percentage of adult population fully vaccinated, and was also ranked number one in the EU for the number of booster vaccines administered.

<span class="mw-page-title-main">COVID-19 vaccination in Canada</span> COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.

COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.

Dr. Shelley Deeks, MD, MHSc, FRCPC, FFAFPM, is a Canadian public health expert who is the chair of the National Advisory Committee on Immunization. Her advertised "specialities include communicable disease control, outbreak investigations, vaccine safety, epidemiology and program evaluation." She is a fellow of the Royal College of Physicians of Canada and the Australian Faculty of Public Health Medicine. Deeks was the executive lead in Ontario's COVID-19 pandemic response in 2020 in her role at Public Health Ontario.

<span class="mw-page-title-main">COVID-19 vaccination in Vietnam</span> Plan to immunize against COVID-19 in Vietnam

The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

Vaccination in Mexico includes the use of vaccines in advancing public health. Mexico has a multi-year program for immunization of children. The immunization of children is fully covered by the government of Mexico. Mexico has an adverse events committee to monitor the adverse effects of vaccination as well as a standing technical advisory group on immunization.

The Australian Technical Advisory Group on Immunisation (ATAGI) is a technical advisory group of the Australian Government. As part of the Department of Health, ATAGI provides advice to the Minister of Health on the immunisation program of Australia and related matters, including the strength of evidence pertaining to existing, new, and emerging vaccines.

The COVID-19 vaccination campaign in Quebec was a provincial effort to distribute and administer vaccines against COVID-19.

<span class="mw-page-title-main">COVID-19 vaccination in Indonesia</span> Plan to immunize against COVID-19

The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.

<span class="mw-page-title-main">COVID-19 vaccination in Brazil</span> Plan to immunize against COVID-19

The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.

COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer-BioNTech COVID-19 vaccine were administered. In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. By the beginning of 2022, over 80 percent of Ontarians had received their first dose.

References

  1. 1 2 "Recommendations on the use of COVID-19 vaccines". Government of Canada. March 16, 2021.
  2. ↑ Desai, Shalini; lsmail, Shainoor J; Lerch, Robert; Warshawsky, Bryna F; Gemmill, Ian (2015). "Canada's National Advisory Committee on Immunization: Celebrating 50 years". The Canadian Journal of Infectious Diseases & Medical Microbiology. 26 (3): 126–128. doi: 10.1155/2015/431428 . PMC   4507835 . PMID   26236351.
  3. 1 2 "National Advisory Committee on Immunization Terms of Reference" (PDF). NITAG Resource. Retrieved September 15, 2021.
  4. 1 2 "National Advisory Committee on Immunization (NACI): Membership and representation". Government of Canada. May 27, 2024.
  5. ↑ Miller, Adam (March 30, 2021). "Why Canada is suspending use of AstraZeneca vaccine in people under 55". CBC News. Retrieved April 7, 2021.
  6. 1 2 Aiello, Rachel (March 3, 2021). "Second doses of COVID-19 vaccines can be given up to 4 months after first, NACI now says". CTV News . Retrieved June 2, 2021.
  7. ↑ Pinkerton, Charlie (March 8, 2021). "Pfizer not consulted by NACI on spacing out doses; warns against 4-month gap". iPolitics . Retrieved June 2, 2021.
  8. ↑ Canada, Public Health Agency of (May 28, 2021). "NACI updated COVID-19 vaccine statement, May 28, 2021: Summary". Canada.ca. NACI. Retrieved June 4, 2021.
  9. ↑ Ghosh, Twinkle. "2nd COVID-19 shots should be offered 'as soon as possible': NACI". Global News . Retrieved June 4, 2021.
  10. 1 2 Dunham, Jackie (May 4, 2021). "NACI accused of contributing to confusion, hesitancy over 'preferred' vaccines guidance". CTV News. Bell Media. Retrieved May 9, 2021.
  11. ↑ Rabson, Mia (May 6, 2021). "NACI chair says advice not meant to give AstraZeneca recipients vaccine remorse". Canadian Press. Retrieved May 9, 2021.
  12. ↑ Aziz, Saba (June 1, 2021). "NACI recommends mixing AstraZeneca, Pfizer, Moderna COVID-19 vaccines". Global News. Retrieved July 27, 2021.
  13. ↑ Aziz, Saba (June 2, 2021). "Experts fear AstraZeneca COVID-19 vaccine wastage after NACI recommends mixing doses - National | Globalnews.ca". Global News. Retrieved July 27, 2021.
  14. ↑ Neustaeter, Brooklyn (July 19, 2021). "Some cruise lines not accepting passengers with mixed COVID-19 vaccinations". CTV News. Retrieved July 27, 2021.
  15. ↑ Reynolds, Christopher (July 20, 2021). "Government expects foreign states' wariness of mix-and-match vaccination to 'evolve'". CTV News. Retrieved July 27, 2021.
  16. ↑ Major, Darren (July 16, 2021). "Government working with other countries to recognize Canadians with mixed doses as fully vaccinated". CBC News. Retrieved July 27, 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.